Pulmatrix (NASDAQ:PULM) Shares Pass Below 50-Day Moving Average – What’s Next?

Pulmatrix, Inc. (NASDAQ:PULM) shares passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.32 and traded as low as $1.22. Pulmatrix shares last traded at $1.32, with a volume of 13,316 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pulmatrix in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Pulmatrix presently has a consensus rating of “Sell”.

Pulmatrix Stock Performance

The firm has a market capitalization of $4.82 million, a P/E ratio of -1.07 and a beta of 1.95. The business’s fifty day moving average price is $1.32 and its two-hundred day moving average price is $2.36.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings results on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share for the quarter.

Hedge Funds Weigh In On Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. DRW Securities LLC acquired a new stake in Pulmatrix, Inc. (NASDAQ:PULM) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. Hedge funds and other institutional investors own 11.84% of the company’s stock.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).